Education
About Us
Working with TipRanks
Follow Us
RegenXBio Inc. (RGNX)
:RGNX
Earnings Data
Report Date
Mar 03, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.74Last Year’s EPS
-1.01Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and achievements in clinical development and financial positioning. However, there are regulatory challenges and uncertainties, particularly concerning international approvals and the use of external controls. Despite these challenges, the overall sentiment leans positive due to strong pipeline advancements and financial stability.Company Guidance
Progress in RGX-202 Program for Duchenne
Enrollment completed ahead of schedule for the AFFINITY DUCHENNE pivotal trial. Strong safety and efficacy profile in Phase I/II with no serious adverse events reported. Top-line data expected in early Q2 2026, with a BLA submission planned for mid-2026.
Advancements in RGX-121 for MPS II
Positive 12-month data delivered to FDA, with no observations during site inspections. The program is on track for potential approval by February 2026.
Strong Financial Position
Cash, cash equivalents, and marketable securities of $302 million as of September 30, 2025. Cash runway expected to fund operations into early 2027, with potential nondilutive financing opportunities available.
Completion of Enrollment in Wet AMD Studies
Over 1,200 patients enrolled across 200 sites in the global Phase III studies for subretinal wet AMD, marking the largest global gene therapy program ever conducted.
RGNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RGNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $11.61 | $11.17 | -3.79% |
Aug 07, 2025 | $8.23 | $7.90 | -4.01% |
May 12, 2025 | $7.97 | $8.18 | +2.63% |
Mar 13, 2025 | $6.55 | $6.72 | +2.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does RegenXBio Inc. (RGNX) report earnings?
RegenXBio Inc. (RGNX) is schdueled to report earning on Mar 03, 2026, Before Open (Confirmed).
What is RegenXBio Inc. (RGNX) earnings time?
RegenXBio Inc. (RGNX) earnings time is at Mar 03, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RGNX EPS forecast?
RGNX EPS forecast for the fiscal quarter 2025 (Q4) is -0.74.